A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi

Camilla Rothe, Derek J. Sloan, Patrick Goodson, Jean Chikafa, Mavuto Mukaka, Brigitte Denis, Tom Harrison, Joep J. van Oosterhout, Robert S. Heyderman, David G. Lalloo, Theresa Allain, Nicholas A. Feasey

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)

Abstract

Introduction:Cryptococcal meningitis is the most common neurological infection in HIV infected patients in Sub Saharan Africa, where gold standard treatment with intravenous amphotericin B and 5 flucytosine is often unavailable or difficult to administer. Fluconazole monotherapy is frequently recommended in national guidelines but is a fungistatic drug compromised by uncertainty over optimal dosing and a paucity of clinical end-point outcome data.Methods:From July 2010 until March 2011, HIV infected adults with a first episode of cryptococcal meningitis were recruited at Queen Elizabeth Central Hospital, Blantyre, Malawi. Patients were treated with oral fluconazole monotherapy 800 mg daily, as per national guidelines. ART was started at 4 weeks. Outcomes and factors associated with treatment failure were assessed 4, 10 and 52 weeks after fluconazole initiation.Results:Sixty patients were recruited. 26/60 (43%) died by 4 weeks. 35/60 (58.0%) and 43/56 (77%) died or failed treatment by 10 or 52 weeks respectively. Reduced consciousness (Glasgow Coma Score 3 of 5) and confusion (Abbreviated Mental Test Score

Original languageEnglish
Article numbere67311
Number of pages6
JournalPLoS One
Volume8
Issue number6
DOIs
Publication statusPublished - 28 Jun 2013

Fingerprint

Dive into the research topics of 'A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi'. Together they form a unique fingerprint.

Cite this